NFSG
RNAC icon

Newbridge Financial Services Group’s Cartesian Therapeutics RNAC Stock Holding History

Newbridge Financial Services Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$1.95K – 1207
2024
Q1 		$1.95K Hold
100
– – ﹤0.01% 995
2023
Q4 		$2.07K Hold
100
– – ﹤0.01% 963
2023
Q3 		$3.18K Buy
+100
New +$3.34K ﹤0.01% 1022

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Newbridge Financial Services Group's RNAC Position: Q2 2024 in Review

Newbridge Financial Services Group sold out of Cartesian Therapeutics (RNAC) in Q2 2024, closing a stake of 100 shares — an estimated $1.95K sold.

Newbridge Financial Services Group first reported a position in RNAC in Q3 2023 and held it in 3 quarters. The position peaked at $3.18K in Q3 2023. 61 funds tracked by Wall St. Rank hold RNAC as of Q2 2024.

  • Newbridge Financial Services Group reported no remaining Cartesian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Newbridge Financial Services Group sold 100 Cartesian Therapeutics shares in Q2 2024, an estimated $1.95K.
  • Newbridge Financial Services Group first reported a position in Cartesian Therapeutics in Q3 2023 and held it in 3 quarters.
  • Newbridge Financial Services Group's Cartesian Therapeutics position peaked at $3.18K in Q3 2023.
  • 61 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2024.

Based on Newbridge Financial Services Group's 13F filing for Q2 2024, filed 11 Sep 2024.